Coya Therapeutics Inc

NASDAQ:COYAUnited States

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

Contact Information

Headquarters

5850 San Felipe St., Suite 500HOUSTON, TX, United States 77057

Phone

650-739-3939

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Howard Berman

President, Chief Medical Officer

Fred Grossman

Chief Financial Officer, Chief Operating Officer

David Snyder

Director

Wilbur Ross

Director

Dieter Weinand